 | William Blair Weighs in on Actinium Pharmaceuticals, Inc.'s Q1 2021 Earnings (NYSEAMERICAN:ATNM)
americanbankingnews.com - April 19 at 1:28 AM |
 | Glenmark Pharma’s API arm files papers with Sebi to unlock value via IPO
msn.com - April 17 at 7:55 AM |
 | Global Healthcare API Market (2020 to 2025) - Featuring Apple, General Electric and Cerner Among Others - ResearchAndMarkets.com
ca.finance.yahoo.com - April 13 at 8:23 AM |
| Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Forecasted to Post Q2 2021 Earnings of ($0.62) Per Share
americanbankingnews.com - April 9 at 8:18 AM |
 | Novel Cancer Therapy Phase 3 Trial Expects To Be Completed Shortly
markets.businessinsider.com - April 6 at 11:36 AM |
| Actinium Pharmaceuticals (NYSEMKT:ATNM) Is In A Good Position To Deliver On Growth Plans
finance.yahoo.com - April 5 at 7:09 AM |
| Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Releases Earnings Results, Meets Estimates
americanbankingnews.com - April 2 at 8:06 AM |
| Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) PT Lowered to $57.00 at HC Wainwright
americanbankingnews.com - April 1 at 10:18 AM |
| Actinium to Participate in the Cell & Gene Meeting on the Mediterranean
finance.yahoo.com - March 31 at 6:48 PM |
 | Actinium initiates patient enrollment in Iomab-ACT trial prior to CD19 CAR t-cell therapy
seekingalpha.com - March 26 at 12:36 AM |
|
| Actinium Announces Completion of Enrollment of Second Dose Cohort in Actimab-A Venetoclax Combination Trial for Patients with R/R AML
finance.yahoo.com - March 25 at 9:34 AM |
| Actinium Announces Initiation of Patient Enrollment in Iomab-ACT Trial for Targeted Conditioning Prior to CD19 CAR T-Cell Therapy
finance.yahoo.com - March 24 at 7:58 AM |
| Actinium to Highlight Expansion of Targeted Conditioning Portfolio at AACR with Next-Generation Actinium-225-Based CD45 Targeting ARC
finance.yahoo.com - March 11 at 7:37 AM |
| Actinium Announces Appointment of Mark Kubik, MBA as Chief Business Officer
finance.yahoo.com - March 3 at 7:43 AM |
| Actinium Announces Participation in H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - March 2 at 9:11 AM |
| Actinium Showcases Targeted Conditioning Program with 2 Oral Presentations Highlighting Iomab-B and Pivotal Phase 3 SIERRA Trial at 2021 Transplantation & Cellular Therapy Annual Meeting
finance.yahoo.com - February 11 at 8:05 AM |
| Actinium Announces Participation in BIO CEO & Investor Digital Conference
finance.yahoo.com - February 10 at 7:37 AM |
| Actinium to Participate in a Fireside Chat at the B. Riley Oncology Investor Conference
finance.yahoo.com - January 20 at 8:15 AM |
| Actinium Pharma Announces Research Collaboration With Astellas - Quick Facts
markets.businessinsider.com - January 13 at 8:01 AM |
| Actinium and Astellas Announce Research Collaboration Focused on Novel Actinium-225 Based Targeted Radiotherapies
finance.yahoo.com - January 13 at 7:23 AM |
 | Actinium Says DMC Recommends Phase 3 SIERRA Trial Continue To Full Enrolment Of 150 Patients
nasdaq.com - December 29 at 9:45 AM |
| Actinium Announces Successful Pre-Planned Ad Hoc Interim Analysis of Phase 3 SIERRA trial
finance.yahoo.com - December 29 at 8:55 AM |
 | ATNM.A - Actinium Pharmaceuticals Inc Profile | Reuters
reuters.com - December 26 at 12:53 AM |
| Actinium Pharmaceuticals (ATNM) Gains As Market Dips: What You Should Know
finance.yahoo.com - December 9 at 8:29 PM |
| Actinium Highlights Presence at Targeted Radiopharmaceuticals Summit
finance.yahoo.com - December 9 at 8:50 AM |
 | Benzinga Global Small Cap Conference Day 1 Recap: Sorrento, Arcimoto And Much More
benzinga.com - December 8 at 8:26 PM |
| Actinium Reveals 67 Percent Overall Response Rate In Actimab-A Venetoclax Combination Trial
nasdaq.com - December 8 at 9:52 AM |
| Actinium Reports 67 Percent Overall Response Rate in First Cohort in Actimab-A Venetoclax Combination Trial in Relapsed and Refractory AML at ASH
finance.yahoo.com - December 8 at 9:16 AM |
|
| Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 75% of Total Patient Enrollment at the 62nd American Society of Hematology Annual Meeting
finance.yahoo.com - December 7 at 8:48 AM |
| Actinium Presents Interim Data from Actimab-A CLAG-M Phase 1 Combination Trial at the 62nd American Society of Hematology Annual Meeting
finance.yahoo.com - December 7 at 7:43 AM |
| Actinium Pharmaceuticals: Our Bullish View Is Intact On Promising Early Stage Results
seekingalpha.com - December 5 at 9:07 PM |
| Is Actinium Pharmaceuticals (ATNM) A Good Stock To Buy Now?
finance.yahoo.com - December 2 at 11:02 PM |
| Actinium Appoints Mary Mei Chen, M.D., Ph.D. as Vice President of Clinical Development
finance.yahoo.com - December 1 at 7:32 AM |
| Actinium Pharma Highlights Intellectual Property Portfolio For Apamistamab
nasdaq.com - November 23 at 8:11 AM |
| Actinium Highlights Foundational Patents Covering the Composition of Apamistamab Antibody and Iomab-B Antibody Radiation Conjugate for Targeted Conditioning Until 2037 and Recent EU Patent Activity
finance.yahoo.com - November 23 at 8:11 AM |
| Actinium Strengthens Leadership Team with Appointment of Dr. Avinash Desai as Executive Vice President of Clinical Development, Operations and Medical Affairs
finance.yahoo.com - November 19 at 7:41 AM |
| ATNM Nov 2020 2.500 call(CONTRA
finance.yahoo.com - November 19 at 1:08 AM |
| Actinium to Participate in the Alliance Global Partners' Virtual Healthcare Symposium
finance.yahoo.com - November 16 at 7:20 AM |
| Actinium to Host KOL Call on November 11th Featuring Actimab-A AML Combination Trials
finance.yahoo.com - November 11 at 8:08 AM |
| Actinium Announces Actimab-A Venetoclax First-in-Human Data Accepted for Poster Presentation at the 62nd American Society of Hematology Annual Meeting
finance.yahoo.com - November 4 at 1:15 PM |
| Actinium Announces Two Oral Presentations Featuring Data and Findings from the Phase 3 SIERRA Trial of Iomab-B at the 62nd American Society of Hematology Annual Meeting
finance.yahoo.com - November 4 at 1:15 PM |
| 100% Remission Rate Reported in Third Dose Cohort of Actimab-A CLAG-M Phase 1 Combination Trial in Patients with Relapsed or Refractory AML
finance.yahoo.com - November 4 at 1:15 PM |
| Actinium Sees Multiple Milestones In Q4 From ARC Pipeline Incl Phase 3 Data From SIERRA Trial
markets.businessinsider.com - October 28 at 9:56 AM |
| Actinium Pharmaceuticals, Inc. Provides Corporate Update and Year-End 2020 Outlook
finance.yahoo.com - October 28 at 7:27 AM |
| Actinium Pharma cheers National Institutes of Health grant to study novel Iomab-ACT
seekingalpha.com - October 21 at 9:08 AM |
| Actinium Pharmaceuticals, Inc. Awarded Grant by National Institutes of Health to Study Novel Iomab-ACT Targeted Conditioning with a CD19 CAR T-Cell Therapy
finance.yahoo.com - October 21 at 7:40 AM |
| Actinium Pharmaceuticals, Inc. Expands R&D Capabilities with New Research Facility to Enhance Development of Next Generation Antibody Radiation Conjugates Leveraging Its Proprietary AWE Platform
finance.yahoo.com - October 14 at 10:10 PM |
| Actinium Pharmaceuticals expands R&D capabilities with new research facility in New York City
seekingalpha.com - October 14 at 12:09 PM |
| Actinium concludes dosing cohort in Phase 1 Actimab-A/venetoclax combination trial
seekingalpha.com - September 23 at 9:37 AM |
| Actinium Pharmaceuticals Successfully Completes First Dosing Cohort in the Phase 1 Study of Actimab-A and Venetoclax Combination Therapy in Relapsed/Refractory AML Patients
finance.yahoo.com - September 23 at 9:37 AM |
